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Background
Obesity and obstructive sleep apnea tend to coexist and are associated with inflam-
mation, insulin resistance, dyslipidemia, and high blood pressure, but their causal 
relation to these abnormalities is unclear.
Methods
We randomly assigned 181 patients with obesity, moderate-to-severe obstructive sleep 
apnea, and serum levels of C-reactive protein (CRP) greater than 1.0 mg per liter to 
receive treatment with continuous positive airway pressure (CPAP), a weight-loss 
intervention, or CPAP plus a weight-loss intervention for 24 weeks. We assessed the 
incremental effect of the combined interventions over each one alone on the CRP 
level (the primary end point), insulin sensitivity, lipid levels, and blood pressure.
Results
Among the 146 participants for whom there were follow-up data, those assigned to 
weight loss only and those assigned to the combined interventions had reductions 
in CRP levels, insulin resistance, and serum triglyceride levels. None of these 
changes were observed in the group receiving CPAP alone. Blood pressure was re-
duced in all three groups. No significant incremental effect on CRP levels was 
found for the combined interventions as compared with either weight loss or CPAP 
alone. Reductions in insulin resistance and serum triglyceride levels were greater in 
the combined-intervention group than in the group receiving CPAP only, but there 
were no significant differences in these values between the combined-intervention 
group and the weight-loss group. In per-protocol analyses, which included 90 par-
ticipants who met prespecified criteria for adherence, the combined interventions 
resulted in a larger reduction in systolic blood pressure and mean arterial pressure 
than did either CPAP or weight loss alone.
Conclusions
In adults with obesity and obstructive sleep apnea, CPAP combined with a weight-
loss intervention did not reduce CRP levels more than either intervention alone. In 
secondary analyses, weight loss provided an incremental reduction in insulin resis-
tance and serum triglyceride levels when combined with CPAP. In addition, adher-
ence to a regimen of weight loss and CPAP may result in incremental reductions in 
blood pressure as compared with either intervention alone. (Funded by the National 
Heart, Lung, and Blood Institute; ClinicalTrials.gov number, NCT0371293.)
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A vailable clinical data derived largely from observational studies link obstructive sleep apnea1 to proatheroscle-
rotic risk factors, including insulin resistance,2 
dyslipidemia, hypertension,3 and inflammation.4 
Obesity and obstructive sleep apnea are strongly 
associated.5-8 Like obstructive sleep apnea, obe-
sity is linked to insulin resistance,6 dyslipidemia,9 
hypertension,9,10 and inflammation.10 However, 
the relative causal roles that obstructive sleep ap-
nea and obesity play in these abnormalities is un-
clear.6,11,12 The interrelationships between obesity 
and obstructive sleep apnea are complex and bi-
directional, and they cannot be confidently dis-
cerned in observational studies. Randomized tri-
als have shown the beneficial effects of weight loss 
on cardiovascular risk factors. However, even mod-
est reductions in body weight are associated with 
changes in obstructive sleep apnea, with a 10% 
reduction in body weight predicting an approxi-
mate change of 26 to 32% in the apnea–hypop-
nea index (AHI).13 Previous trials assessing the 
effects of weight loss on cardiovascular risk fac-
tors have neither assessed the effect of sleep-dis-
ordered breathing nor included a controlled in-
tervention for obstructive sleep apnea. Conversely, 
trials of continuous positive airway pressure (CPAP) 
therapy have not included a control intervention 
for obesity. Furthermore, the incremental benefit 
of a weight-loss intervention plus CPAP as com-
pared with each intervention alone in reducing 
cardiovascular risk factors is unknown. We eval-
uated the incremental effect of CPAP combined 
with a weight-loss intervention over the effect of 
each intervention alone on subclinical inflamma-
tion, insulin resistance, dyslipidemia, and blood 
pressure in patients with obesity and obstructive 
sleep apnea.
Me thods
Study Design
In this randomized, parallel-group, 24-week tri-
al, we compared the effects of CPAP, weight loss, 
or both CPAP and weight loss in adults with obe-
sity (body-mass index [the weight in kilograms 
divided by the square of the height in meters], 
≥30), moderate-to-severe obstructive sleep apnea 
(AHI, ≥15 apnea or hypopnea events per hour), 
and a serum level of C-reactive protein (CRP) 
greater than 1.0 mg per liter. Detailed criteria for 
inclusion and exclusion are provided in Table S1 
in the Supplementary Appendix, available with the 
full text of this article at NEJM.org.
Potential participants were screened with the 
use of a home-based sleep monitor (ApneaLink, 
ResMed) for 1 or 2 nights. If this test yielded an 
AHI score of 10 or more events per hour, we per-
formed 12-channel diagnostic polysomnography 
in the sleep laboratory for a full night. Patients 
with a polysomnogram that showed an AHI of 15 
or more events per hour were randomly assigned 
to a study group. Randomization was conducted 
with a permuted-block design, with stratification 
according to sex, status with respect to statin use, 
and enrollment site (the Hospital of the Univer-
sity of Pennsylvania or the Philadelphia Veterans 
Affairs Medical Center).
The study was approved by the institutional re-
view boards of the University of Pennsylvania and 
the Philadelphia Veterans Affairs Medical Center. 
Participants provided written informed consent. 
ApneaLink devices and CPAP machines were pro-
vided at no cost by ResMed, which had no role in 
study design, data accrual or analysis, or manu-
script preparation. The first and last authors vouch 
for the accuracy and completeness of the data 
and for the fidelity of the study to the protocol.
Interventions
In the CPAP and combined-intervention groups, 
participants underwent an overnight in-laborato-
ry sleep study to allow for individual calibration 
of the CPAP therapy each participant would re-
ceive. Nightly CPAP therapy was provided there-
after through a fixed-pressure or autoadjusting 
CPAP device (ResMed). Adherence to CPAP ther-
apy was monitored weekly by means of a wireless 
router attached to the CPAP device (ResTraxx, 
ResMed).
Participants in the weight-loss group and 
those in the combined-intervention group had 
individual weekly counseling sessions. The goals 
for caloric intake were set at 1200 to 1500 kcal 
per day for participants weighing less than 114 kg 
and at 1500 to 1800 kcal per day for those weigh-
ing 114 kg or more. Dietary composition was 
aligned with recommendations from the National 
Cholesterol Education Program (NCEP). Self-
selected foods within the framework of the NCEP 
diet were prescribed for the first 2 weeks. For 
weeks 3 to 19, a more structured diet was pre-
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scribed, including two to three liquid-meal re-
placements per day.14 Unsupervised exercise was 
initiated at week 4, starting with four 15-minute 
weekly sessions that increased progressively to 
four 50-minute weekly sessions by week 15. This 
target for level of activity was chosen because of 
its association with long-term maintenance of 
weight loss. Cognitive-behavioral strategies, in-
cluding self-monitoring, goal setting, stimulus 
control, problem solving (to address problems 
with adherence to recommendations on diet and 
exercise), and relapse prevention, were used to 
facilitate and maintain weight loss.15
Study Assessments and End Points
Assessments were performed at baseline and at 
8 and 24 weeks after the initiation of therapy. 
Serum levels of CRP and lipoproteins were mea-
sured after an overnight fast. Insulin sensitivity 
was assessed with the use of the frequently sam-
pled intravenous glucose-tolerance test, which 
allowed for calculation of the insulin sensitivity 
index with Bergman’s minimal model.16 (Analytic 
methods are described in detail in the Supple-
mentary Appendix.)
The primary end point was the serum CRP 
level. Secondary end points included insulin sen-
sitivity and atherogenic dyslipidemia (determined 
by measuring serum levels of triglycerides, high-
density lipoprotein [HDL] cholesterol, low-densi-
ty lipoprotein [LDL] cholesterol, and LDL-particle 
concentration). Exploratory end points included 
systolic blood pressure, mean arterial pressure, 
pulse pressure, and HDL-particle concentration.
Statistical Analysis
Our primary analysis was based on a modified 
intention-to-treat population, defined for the pur-
poses of the study as all participants who were 
randomly assigned to a study group and for whom 
there was at least one observation after random-
ization. Additional per-protocol analyses were per-
formed to investigate the causal relation between 
obstructive sleep apnea or obesity and underlying 
metabolic abnormalities. These analyses were 
based on the principle that any incremental ben-
efit of weight loss combined with effective CPAP 
treatment, as compared with the benefit of effec-
tive CPAP treatment alone, can be attributed to 
effects of obesity that are independent of the ef-
fects of obstructive sleep apnea. Conversely, any 
incremental benefit of effective CPAP therapy 
combined with weight loss, as compared with 
weight loss alone, can be attributed to effects of 
obstructive sleep apnea that are independent of 
the effects of obesity. For these assumptions to 
be valid, the estimation of between-group differ-
ences requires actual reductions in body weight 
and obstructive sleep apnea. Accordingly, our per-
protocol analyses were restricted to participants 
who met minimum requirements for weight loss 
(at least 5% of baseline weight) and adherence to 
CPAP therapy (use for an average of at least 4 hours 
per night on at least 70% of the total number of 
nights). On the basis of previous studies evaluat-
ing the effects of CPAP therapy alone17 and weight 
loss alone18 on CRP levels, we powered the trial 
to detect standardized between-group differenc-
es in the change from the baseline CRP level of at 
least 0.53 mg per liter in the modified intention-
to-treat population and at least 0.79 mg per liter 
in the per-protocol population, with 90% power, 
allowing for a type I error rate of 0.05.
The effects of the interventions on end points 
were analyzed with the use of general linear 
mixed models, with all measurements available at 
24 weeks used to estimate intervention effects.19 
Restricted maximum-likelihood estimation was 
used, and an unstructured covariance matrix was 
specified to adjust for within-participant cluster-
ing resulting from the repeated-measures design. 
Individual measures of growth were modeled as 
a function of randomly assigned group, time, and 
the interaction between group and time.
The primary comparisons of interest were the 
24-week change in the CRP level among partici-
pants in the modified intention-to-treat popula-
tion who were assigned to the combined interven-
tion as compared with the changes among those 
assigned to CPAP alone and those assigned to 
weight loss alone. To account for two primary 
comparisons, a Bonferroni-adjusted significance 
level was set at 0.025 for each comparison. All 
other analyses were considered secondary, with 
a nominal significance level of 0.05. Accordingly, 
any nominally significant P values in secondary 
analyses should be interpreted conservatively, giv-
en an increased type I error rate introduced by 
multiple comparisons. Considering the number of 
comparisons made for a total of 10 end points, 
up to two significant tests of incremental bene-
fit (P<0.05) would be expected on the basis of 
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chance alone in each of the study populations ana-
lyzed (the modified intention-to-treat and per-
protocol samples). Although this study was not 
designed to compare the effects of CPAP alone 
and weight loss alone, we also provide the results 
of exploratory analyses for these pairwise com-
parisons. Data on the CRP level were log-trans-
formed because of their skewed distribution. 
Analyses were performed with SAS software, 
version 9.2 (SAS Institute).
R esult s
Study Participants
A total of 544 persons were screened and 181 
underwent randomization (Fig. 1). Baseline char-
acteristics were similar among the three groups 
(Table 1). Of the 181 participants, 35 dropped out 
of the trial before the follow-up visit at 8 weeks, 
and an additional 10 participants dropped out 
after that visit; a total of 136 participants com-
pleted the study. The modified intention-to-treat 
analyses included the 146 participants who un-
derwent at least one assessment for the study end 
points after the initiation of therapy.
The decline in body weight was similar in the 
weight-loss and combined-intervention groups 
(6.8 kg and 7.0 kg, respectively); there was no 
discernible decline in body weight in the CPAP 
group (Fig. S1A in the Supplementary Appendix). 
The average duration of CPAP use was 4.0 hours 
per night, with no significant differences between 
the CPAP and combined-intervention groups. 
Among all three groups, the adherence criteria 
for inclusion in the per-protocol analyses were 
met by 90 participants: 39 in the CPAP group, 27 
in the weight-loss group, and 24 in the combined-
intervention group. (Table S2 in the Supplementary 
Appendix shows the baseline characteristics of 
participants who met the prespecified adherence 
criteria.)
CRP Levels
The combined interventions did not have a signifi-
cant incremental effect on CRP levels, as com-
pared with either weight loss alone or CPAP alone, 
in either the modified intention-to-treat popula-
tion (Fig. 2A) or the per-protocol population (Fig. 
2B). In both the modified intention-to-treat pop-
ulation and the per-protocol population, the lat-
ter comprising participants who met prespecified 
adherence criteria, the CRP level was significantly 
reduced at 24 weeks in the weight-loss and com-
bined-intervention groups but not in the CPAP 
group, and the reduction in the CRP level was 
greater in the weight-loss group than in the CPAP 
group.
Insulin Sensitivity
In the modified intention-to-treat analyses, insu-
lin sensitivity increased in the weight-loss and 
combined-intervention groups at 24 weeks but 
not in the CPAP group. The increase in insulin 
sensitivity was significantly greater in the com-
bined-intervention group than in the CPAP group 
(Fig. 3A), but the difference between the com-
bined-intervention group and the weight-loss group 
was not significant. The results of the per-proto-
col analyses were similar (Fig. 3A).
Dyslipidemia
In the modified intention-to-treat population, the 
reduction in serum triglyceride levels at 24 weeks 
was greater in the combined-intervention group 
than in the CPAP group; there was no significant 
difference in the change in triglyceride levels be-
tween the combined-intervention group and the 
weight-loss group (Fig. 3B). The results were simi-
lar in the per-protocol population (Fig. 3B). Se-
rum triglyceride levels were significantly reduced 
at 24 weeks in the weight-loss and combined-
intervention groups but not in the CPAP group.
Changes in LDL cholesterol levels at 24 weeks 
did not differ significantly among the three study 
groups in either the modified intention-to-treat 
population or the per-protocol population (Fig. S1B 
in the Supplementary Appendix). In the modi-
fied intention-to-treat population, a reduction in 
LDL cholesterol levels was observed in the weight-
loss group. In the per-protocol population, LDL 
cholesterol levels were reduced in the combined-
intervention group and the weight-loss group 
but not in the CPAP group. Changes in HDL 
cholesterol levels from baseline to 24 weeks were 
similar among the three study groups (Fig. S1C 
in the Supplementary Appendix). There was no 
significant change in HDL cholesterol levels at 
24 weeks in any of the study groups. The find-
ings for LDL-particle and HDL-particle concen-
trations (Fig. S1D and S1E in the Supplementary 
Appendix) were similar to those for LDL and HDL 
cholesterol levels, respectively.
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Blood Pressure
In the modified intention-to-treat population, sys-
tolic blood pressure was reduced at 24 weeks in 
all three study groups (Fig. 3C), with no signifi-
cant between-group differences. In the per-pro-
tocol population, the reduction in systolic blood 
pressure at 24 weeks was greater in the combined-
intervention group (14.1 mm Hg) than in the 
weight-loss group (6.8 mm Hg) and the CPAP 
group (3.0 mm Hg) (Fig. 3C). Mean arterial pres-
sure also decreased in all three study groups in 
the modified intention-to-treat population, with 
no significant between-group differences (Fig. S2A 
in the Supplementary Appendix). In the per-pro-
181 Underwent randomization
544 Patients were assessed for eligibility
363 Were excluded
44 Were not interested in continuing study
319 Met exclusion criteria
151 Had an AHI <15 events/hr
37 Had a CRP value of <1 mg/liter
22 Were excluded for safety reasons
19 Did not pass motor vehicle questionnaire
17 Had blood pressure >160/95 mm Hg
13 Had a BDI score ≥29 points
10 Were lost to follow-up
7 Had a BMI <30 
5 Had fasting blood glucose >125 mg/dl
38 Had other reasons
61 Were assigned to the weight-loss
group
58 Were assigned to the CPAP
group
55 Started treatment 56 Started treatment
62 Were assigned to the combination
group
57 Started treatment
46 Were included in the 8-wk
assessment
50 Were included in the 8-wk
assessment
50 Were included in the 8-wk
assessment
42 Were included in the 24-wk
assessment
48 Were included in the 24-wk
assessment
46 Were included in the 24-wk
assessment
136 Completed the study
Figure 1. Numbers of Patients Who Were Screened, Randomly Assigned to a Study Group, and Included in Analyses.
AHI denotes apnea–hypopnea index, BDI Beck Depression Inventory (in which scores range from 0 to 63, with high-
er scores indicating more severe depression), BMI body-mass index (the weight in kilograms divided by the square 
of the height in meters), CPAP continuous positive airway pressure, and CRP C-reactive protein. To convert the val-
ues for glucose to millimoles per liter, multiply by 0.05551.
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Table 1. Baseline Characteristics of the Study Participants.*
Characteristic
Weight Loss 
(N = 61)
CPAP  
(N = 58)
CPAP and 
Weight Loss 
(N = 62) P Value
Age — yr 48.3 49.8 49.0 0.75
Male sex — no. (%) 36 (59) 35 (60.3) 33 (53.2) 0.70
Race — no. (%)† 0.95
White 33 (54) 34 (59.6) 36 (59.0)
Black 25 (41) 23 (40.4) 25 (41.0)
Mixed or other 3 (5) 1 (1.72) 1 (1.61)
Height — cm 172.5±10 170.2±14.2 165.9±23 0.09
Weight — kg 114.5±21.9 115.1±21.7 111.5±28.1 0.68
Body-mass index‡ 38.1±5.8 39.8±7.1 38.4±6.4 0.29
Cholesterol — mg/dl
Total 188.1±46.1 196.4±46 177.1±44.4 0.07
HDL 43.1±11.7 43.1±10.6 40±12.6 0.23
LDL 116.7±35 123.8±31.1 107±32 0.02
Cholesterol particle size — nm
LDL 20.5 (0.73) 20.5 (0.71) 20.5 (0.65) 0.96
HDL 8.7 (0.32) 8.8 (0.41) 8.7 (0.31) 0.62
Triglycerides — mg/dl 130±72.3 133.1±63.4 145.3±98.5 0.53
Hypertension — no. (%) 25 (41) 26 (45) 24 (39) 0.79
Insulin sensitivity index§ 1.4±0.82 1.2±1.03 1.4±1.14 0.63
Apoprotein — mg/dl
A-I 120.6 (31.2) 125.7 (25.86) 118.7 (32.69) 0.45
B 87.3 (29.98) 92.5 (26.23) 85.1 (24.06) 0.33
High-sensitivity C-reactive protein — mg/liter 0.74
Median 4.4 4.7 4.3
Interquartile range 1.9–8.5 2.5–8.2 2.1–9.3
Blood pressure — mm Hg
Systolic 126.5±10.02 129.9±14.87 123±19.91 0.053
Diastolic 78.9±7.5 80.1±8.98 76.8±13.71 0.22
AHI — events/hr¶ 39.7±20.3 41.2±20.96 47.1±26.86 0.17
Oxygen desaturation index — no. of events/hr
>3% drop from baseline 22.6±18.8 25.5±22.1 27.6±25.7 0.47
>4% drop from baseline 18.3±17.4 20.7±20.4 23.3±24.7 0.44
Sleep time with SpO2 <90% — % 5.0±8.4 6.9±13.8 8.7±15.6 0.29
Mean SpO2 during sleep — %
Nadir 78±14.8 76.7±11.1 73.7±20.7 0.34
Mean 94.8±1.8 94.7±2.3 94.1±2.4 0.17
Arousal index — no. of arousals/hr of sleep 31.7±15.8 37±20.5 39.6±20.1 0.07
Score on Epworth Sleepiness Scale‖ 9.3±4.3 9.8±4.6 8.9±4.8 0.55
Current or former smoker — no. (%) 21 (34) 20 (35) 12 (19) 0.11
Medication use — no. (%)
Statin 12 (20) 12 (21) 13 (21) 0.99
Antihypertensive medication 25 (41) 24 (41) 21 (34) 0.63
* Plus–minus values are means ±SD. Spo2 denotes oxygen saturation level as measured by pulse oximetry. To convert 
values for low-density lipoprotein (LDL), high-density lipoprotein (HDL), and total cholesterol to millimoles per liter, 
multiply by 0.02586. To convert values for triglycerides to millimoles per liter, multiply by 0.01129.
† Race was self-reported.
‡ The body-mass index is the weight in kilograms divided by the square of the height in meters. 
§ The insulin sensitivity index was calculated with the use of values from frequently sampled glucose tolerance tests. 
Higher levels indicate greater insulin sensitivity.
¶ The apnea–hypopnea index (AHI) is the number of apnea and hypopnea episodes per hours of sleep time.
‖ Scores on the Epworth Sleepiness Scale range from 0.0 to 24.0, with higher scores indicating more daytime sleepiness.
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tocol population, the reduction in mean arterial 
pressure was significantly greater in the combined-
intervention group than in either the weight-loss 
group or the CPAP group. In the modified inten-
tion-to-treat population, pulse pressure was sig-
nificantly reduced at 24 weeks only in the com-
bined-intervention group, and there were no 
significant between-group differences (Fig. S2B 
in the Supplementary Appendix). In the per-pro-
tocol population, the reduction in pulse pressure 
was greater in the combined-intervention group 
and weight-loss groups than in the CPAP group.
Sensitivity Analyses
We performed sensitivity analyses in which the 
baseline value was carried forward for partici-
pants in the modified intention-to-treat popula-
tion who had missing follow-up data because of 
early withdrawal from the study (Table S4 in the 
Supplementary Appendix). These analyses showed 
within-group changes that were less pronounced 
than those observed in the primary analysis, but 
the trends were similar.
Adverse Events
Nasal or sinus congestion, nostril irritation, or 
other upper respiratory symptoms were reported 
in 10 participants in the CPAP group, 9 partici-
pants in the weight-loss group, and 10 partici-
pants in the combined-intervention group. Other 
adverse events were much less common (Table S5 
in the Supplementary Appendix). No serious ad-
verse events occurred that were related to the 
study interventions or to study participation.
Discussion
In this randomized trial, CPAP combined with 
weight loss did not have a significant incremen-
tal effect on CRP levels, as compared with either 
CPAP alone or a weight-loss intervention alone. 
Secondary analyses, which should be interpreted 
conservatively, showed that weight loss had an 
incremental effect on insulin resistance and se-
rum triglyceride levels, as compared with CPAP, 
but no significant incremental effects on these 
end points were observed with combination ther-
apy as compared with the weight-loss intervention 
alone. In exploratory analyses, the combination 
of CPAP and the weight-loss intervention was as-
sociated with a larger reduction in blood pressure 
than was either intervention alone among partici-
pants who adhered to the therapeutic regimen.
As reported in previous studies, weight loss 
C
ha
ng
e 
in
 C
R
P 
fr
om
 B
as
el
in
e
(m
g/
lit
er
)
20
0
10
−10
−20
−40
−50
−30
−60
Wk 8 Wk 24
C
ha
ng
e 
in
 C
R
P 
fr
om
 B
as
el
in
e
(m
g/
lit
er
)
20
10
0
−10
−20
−40
−50
−30
−60
Wk 8 Wk 24
B Per-Protocol PopulationA Modified Intention-to-Treat Population
CPAP alone Weight loss+CPAP Weight loss alone
P=0.01
P<0.001
P<0.001
P<0.001
P<0.01
P=0.01
Figure 2. Changes from Baseline in CRP in the Modified Intention-to-Treat and Per-Protocol Populations.
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significantly reduced CRP levels, insulin resis-
tance, dyslipidemia, and blood pressure.20-22 In 
contrast, CPAP therapy did not have a significant 
effect on CRP level, insulin sensitivity, or dyslip-
idemia, even among participants who adhered to 
the therapy. Cross-sectional observational stud-
ies4,23 and prospective observational studies24-27 
have yielded conflicting results regarding the role 
of obstructive sleep apnea in inflammation, but 
the two largest observational studies did not show 
a reduction in CRP levels after 9 to 12 months of 
CPAP therapy in patients with obstructive sleep 
apnea.26,27 Similarly, short-term observational 
studies28,29 have suggested an improvement in 
insulin resistance with CPAP therapy30; however, 
a crossover trial,31 in which insulin resistance was 
measured with the use of homeostatic model 
assessment, an indirect index of hepatic insulin 
sensitivity, did not show changes in insulin re-
sistance after 6 to 12 weeks of CPAP therapy, 
even among participants who adhered to the treat-
ment regimen. Using the frequently sampled in-
travenous glucose-tolerance test, which measures 
whole-body insulin sensitivity,32 we found that 
CPAP monotherapy did not improve insulin sen-
sitivity or enhance the improvement in insulin 
sensitivity associated with weight loss. In con-
trast, weight loss, with or without CPAP, increased 
insulin sensitivity. CPAP monotherapy for 24 weeks 
also did not improve dyslipidemia in our trial, a 
finding that is consistent with the results of a 
recent randomized trial, which showed no sig-
nificant changes in total cholesterol levels after 
24 weeks of CPAP therapy.33
Unlike the other cardiovascular risk factors 
we assessed, blood pressure decreased in the 
CPAP, weight-loss, and combined-intervention 
groups. In analyses including only participants 
who met the prespecified adherence criteria, 
a larger reduction was seen in the combined-
intervention group than in either the weight-loss 
group or the CPAP group. Despite the causal re-
lationship between obstructive sleep apnea and 
hypertension that has been reported in animal 
models and the epidemiologic association34 be-
tween obstructive sleep apnea and hypertension 
in humans, improvements in blood pressure with 
CPAP therapy in clinical studies have been absent 
or remarkably small,35-37 estimated at approxi-
mately 1.3 to 3.0 mm Hg in systolic or diastolic 
blood pressure. However, to the degree that ob-
structive sleep apnea and CPAP activate similar 
or overlapping pathophysiological pathways lead-
ing to hypertension, it was not possible to clearly 
separate their direct effects without the inclusion 
of randomly assigned CPAP and weight-loss in-
terventions, alone and in combination. Our find-
ings suggest that both obstructive sleep apnea 
and obesity have an independent causal relation 
to hypertension.
Our study has limitations. We did not include 
a sham CPAP intervention. However, both sham 
CPAP and the absence of treatment for obstructive 
sleep apnea are considered to be adequate controls 
for an active CPAP intervention.38 In addition, sham 
CPAP is not a perfect placebo, since it may result 
in significant reductions in the number of apnea 
events, increases in the number of hypopnea 
events, and a small impairment in sleep quality.39 
We did not include any group in which no therapy 
was implemented because of ethical considerations 
and because its inclusion was not needed to test our 
hypotheses. Our 24-week attrition rate was high 
(25%). We did not assess ambulatory blood pres-
sure. Finally, our findings cannot be extended to 
populations with diabetes mellitus or mild obstruc-
tive sleep apnea because of our exclusion criteria.
In conclusion, we found that CPAP therapy 
combined with a weight-loss intervention did not 
have a significant incremental effect on CRP lev-
els, as compared with either intervention alone. 
The weight-loss intervention combined with CPAP 
therapy had an incremental effect on insulin re-
sistance and serum triglyceride levels, as com-
pared with CPAP alone, but no significant incre-
mental effects were detected for combination 
therapy as compared with the weight-loss inter-
vention alone, even among participants who ad-
hered to the therapeutic regimen. In an analysis 
that included only participants who adhered to 
the regimen, the combined interventions result-
ed in a larger reduction in blood pressure than 
Figure 3 (facing page). Changes from Baseline in the 
Insulin Sensitivity Index, Serum Triglyceride Levels, 
and Systolic Blood Pressure in the Modified-Intention-
to-Treat and Per-Protocol Populations.
Panel A shows changes in the insulin sensitivity index, 
Panel B changes in serum triglyceride levels, and Panel 
C changes in systolic blood pressure. I bars represent 
95% confidence intervals. P values without brackets 
are for the change from baseline in each group. P val-
ues with brackets are for between-group differences at 
week 24. To convert the values for triglycerides to milli-
moles per liter, multiply by 0.01129.
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either CPAP or weight loss alone. Our study shows 
that a weight-loss intervention is effective as a 
central component of the strategies used to im-
prove the cardiovascular risk-factor profile in pa-
tients with obesity and obstructive sleep apnea.
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